ZDLD13 is a selective, orally active CDK4/CycD3 inhibitor with an IC50 of 0.38 μM; it exhibits potent anti-HCT116 activity by inhibiting colony formation, suppressing invasion and migration, inducing apoptosis, and arresting the cell cycle at the G1 phase; it demonstrates significant tumor growth inhibition in HCT116 xenograft models.